Compare Orion Office REIT Inc (ONL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Orion Office REIT Inc vs Recursion Pharmaceuticals Inc — how do they compare? Orion Office REIT Inc trades at $2.18 (market cap $125.50M), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 17.1× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.64% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Orion Office REIT Inc for 33 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| ONL | RXRX | |
|---|---|---|
Market Cap | $125.50M | $2.14B |
Volume | 303,276 | 30,789,535 |
Sector | Real Estate | Health |
52-Week High | $3.00 | $6.79 |
52-Week Low | $1.93 | $2.84 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $542.43M | $1.66B |
Dividend Yield | 3.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONL trades at $2.20, down 3.08% with a bearish technical signal despite oscillators showing some bullish momentum. The company shows declining revenue from $208M in 2022 to $148M in 2025 with persistent net losses, though Q2 2026 EPS beat expectations. Valuation metrics show low P/S (0.88) and P/B (0.2) ratios, while analyst sentiment is split evenly between Buy and Hold recommendations.
The outlook remains challenging with ongoing revenue declines and negative profitability, though deep valuation discounts and strategic portfolio repositioning offer potential upside. Key risks include high debt levels, office sector headwinds, and execution challenges in turning around financial performance.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
